《val of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization： report of two cases and literature review.》.pdf

Long-termsurvivalofpatientswithhepatocellularcarcinomawith inferiorvenacavatumorthrombustreatedwithsorafenib combinedwithtransarterialchemoembolization： reportoftwocasesandliteratu reVleW Heng-JunGao，LiXu，Yao—JunZhangandMin—ShanChen Abstract Theprognosisofhepatocellularcarcinoma(HCC)withtumorthrombusformationinthemain vascuIature jsextremelypoor．Sorafenib combinedwithtransarterialchemoembolization isanoveI treatmentapproachforadvancedHCC．Inthisstudy，wereporttwoHCCpatientswithinferiorvenacava tumorthrombuswho underwentthecombination treatment．The overalIsurvivaItimesforthesetwo patientswere44monthsand35months，respectively．Ourreportsuggeststhatsorafenibcombinedwith transarteriaIchemoembolizationmaybeaviablechoiceforpatientswithadvancedHCC evenwithinferior venacavatumorthrombus．Furtherstudiesarerequiredtoverifytheefficacyandsafetyofthiscombination therapyforpatientswithadvancedHCCwithinferiorvenacavatumOrthrombus． Keywords HepatOcelluIarcarcinoma，sorafenib，transarterialchemoembolization，inferiorvena cava，tumor thrombus HepalocellularcarcinomafHCC)，oneoflhemoslcommon comparedwithsorafenib5】【1includingHCCwithmainvesseltumor malignantlumorsinlheworld．isincreasinginincidence¨ andisa thrombus．However，bothsorafenibandTACEhaveonlymodest leadingcauseofdeathamongpatientswithIivercirrhosisJ．1nspite survivalbenefitwhenusedalone，highlightingtheurgentneedfora OflhesurveillanceprogramsforHCC．mosIpatientsarediagnosed noveltreatmentapproach。【】 allheintermediateoradvancedstagesforwhichlhereisnocurative TACEhasapotentialstimulatoryeffeclonangiogenesis．This therapy，resultinginadismalprognosis．Theprognosisisparticularly observedeffecliSrelatedl0up—regulationoflocaIangiogenicfactors． poorforpatientswithHCCwithlumorthrombusinlhemain whichinlurnpromotelumorgrowth．increasinglheriskofmetastases vasculature，suchast